Shashank Masaldan
Shashank Masaldan
WEHI, Australia
Verified email at wehi.edu.au
Title
Cited by
Cited by
Year
Targeting copper in cancer therapy: ‘Copper That Cancer
D Denoyer, S Masaldan, S La Fontaine, MA Cater
Metallomics 7 (11), 1459-1476, 2015
3492015
Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration
S Masaldan, AI Bush, D Devos, AS Rolland, C Moreau
Free Radical Biology and Medicine 133, 221-233, 2019
1502019
Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis
S Masaldan, SAS Clatworthy, C Gamell, PM Meggyesy, AT Rigopoulos, ...
Redox biology 14, 100-115, 2018
1132018
Cervical cancer stem cells selectively overexpress HPV oncoprotein E6 that controls stemness and self-renewal through upregulation of HES1
A Tyagi, K Vishnoi, S Mahata, G Verma, Y Srivastava, S Masaldan, ...
Clinical Cancer Research 22 (16), 4170-4184, 2016
652016
Alterations in microRNAs miR-21 and let-7a correlate with aberrant STAT3 signaling and downstream effects during cervical carcinogenesis
G Shishodia, S Shukla, Y Srivastava, S Masaldan, S Mehta, S Bhambhani, ...
Molecular cancer 14 (1), 1-13, 2015
652015
Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution
D Denoyer, HB Pearson, SAS Clatworthy, ZM Smith, PS Francis, ...
Oncotarget 7 (24), 37064, 2016
452016
Guidelines for the use and interpretation of assays for monitoring autophagy 1
D Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ...
Taylor & Francis, 2021
322021
Heterogeneous copper concentrations in cancerous human prostate tissues
D Denoyer, SAS Clatworthy, S Masaldan, PM Meggyesy, MA Cater
The Prostate 75 (14), 1510-1517, 2015
282015
Exploration of effects of emodin in selected cancer cell lines: enhanced growth inhibition by ascorbic acid and regulation of LRP1 and AR under hypoxia‐like conditions
S Masaldan, VV Iyer
Journal of Applied Toxicology 34 (1), 95-104, 2014
282014
Cellular senescence and iron dyshomeostasis in Alzheimer’s disease
S Masaldan, AA Belaidi, S Ayton, AI Bush
Pharmaceuticals 12 (2), 93, 2019
232019
Redox active metals in neurodegenerative diseases
K Acevedo, S Masaldan, CM Opazo, AI Bush
JBIC Journal of Biological Inorganic Chemistry 24 (8), 1141-1157, 2019
212019
Copper accumulation in senescent cells: Interplay between copper transporters and impaired autophagy
S Masaldan, SAS Clatworthy, C Gamell, ZM Smith, PS Francis, D Denoyer, ...
Redox biology 16, 322-331, 2018
132018
Antioxidant and antiproliferative activities of methanolic extract of Aloe vera leaves in human cancer cell lines
S Masaldan, VV Iyer
J. Pharm. Res 4 (8), 2791-2796, 2011
132011
Copper Ionophores as Novel Antiobesity Therapeutics
PM Meggyesy, S Masaldan, SAS Clatworthy, I Volitakis, DJ Eyckens, ...
Molecules 25 (21), 4957, 2020
22020
Characterization of Selenium Compounds for Anti-ferroptotic Activity in Neuronal Cells and After Cerebral Ischemia–Reperfusion Injury
QZ Tuo, S Masaldan, A Southon, C Mawal, S Ayton, AI Bush, P Lei, ...
Neurotherapeutics, 1-10, 2021
2021
Investigating metal aberrations in cellular senescence
S Masaldan
Deakin University, 2017
2017
Investigating metal aberrations in cancer: from basic science to therapeutic enquiry
S Masaldan, D Denoyer, M Cater
Proceedings of the 19th World Congress on Advances in Oncology and 17th …, 2014
2014
Dynamic reconfiguration of pro-apoptotic BAK on membranes
JJ Sandow, IKL Tan, AS Huang, S Masaldan, JP Bernardini, AZ Wardak, ...
The EMBO Journal, e107237, 0
Prostate cancer cells (PC3s) are more sensitive to copper nanomaterials compared to primary prostate epithelial cells (PrECs)
L Smith, S Masaldan, B Davern, D Denoyer, W Yang, M Cater, ...
The system can't perform the operation now. Try again later.
Articles 1–19